Padial Luis Rodríguez
Cardiac Unit, Hospital Virgen de la Salud, Avda. Barber, 30, 45004 Toledo, Spain.
Expert Rev Cardiovasc Ther. 2008 Jan;6(1):17-25. doi: 10.1586/14779072.6.1.17.
Ezetimibe is a drug that impairs intestinal cholesterol absorption and decreases blood cholesterol levels. It has been shown that added to statins it can achieve a further reduction of low-density lipoprotein-cholesterol of 18-20%, overcoming the increase in absorption that follow the reduction in cholesterol synthesis by statins. Four major outcome trials are underway to study the effect of ezetimibe plus simvastatin in different subsets of high-risk patients: familiar hypercholesterolemia, degenerative aortic stenosis, chronic kidney disease and acute coronary syndrome. Hopefully, in the next few years the information provided by these trials will allow us to further reduce the increasing burden of cardiovascular disease.
依折麦布是一种能抑制肠道胆固醇吸收并降低血液胆固醇水平的药物。研究表明，将其与他汀类药物联用可使低密度脂蛋白胆固醇进一步降低18% - 20%，克服因他汀类药物降低胆固醇合成后导致的吸收增加。目前正在进行四项主要的结果试验，以研究依折麦布加辛伐他汀在不同高危患者亚组中的效果：家族性高胆固醇血症、退行性主动脉瓣狭窄、慢性肾病和急性冠脉综合征。有望在未来几年，这些试验所提供的信息能让我们进一步减轻不断增加的心血管疾病负担。
